Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | cell division protein kinase 2,cdc2-related kinase | 0.0044 | 1 | 1 |
Echinococcus granulosus | 5'partial|cyclin dependent kinase 1 | 0.0044 | 1 | 1 |
Leishmania major | cell division related protein kinase 2,cdc2-related kinase | 0.0044 | 1 | 1 |
Trypanosoma brucei | cdc2-related kinase 3 | 0.0044 | 1 | 1 |
Echinococcus granulosus | cyclin dependent kinase 1 | 0.0044 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0044 | 0.982 | 0.982 |
Echinococcus granulosus | cyclin dependent kinase 5 | 0.0044 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0043 | 0.959 | 0.959 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0043 | 0.959 | 0.959 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclin A, putative | 0.0043 | 0.959 | 0.959 |
Echinococcus multilocularis | cyclin dependent kinase 5 | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0043 | 0.959 | 0.959 |
Entamoeba histolytica | cyclin, putative | 0.0043 | 0.959 | 0.959 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0043 | 0.959 | 0.959 |
Trichomonas vaginalis | cyclins, putative | 0.0043 | 0.959 | 0.959 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.959 | 0.959 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0044 | 1 | 1 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0043 | 0.959 | 0.959 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0044 | 1 | 1 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.003 | 0.4389 | 0.4389 |
Echinococcus granulosus | cyclin B | 0.0043 | 0.959 | 0.959 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0044 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0044 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CDK | 0.0044 | 1 | 1 |
Schistosoma mansoni | cyclin B | 0.0043 | 0.959 | 0.959 |
Trypanosoma brucei | cdc2-related kinase 1 | 0.0044 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.959 | 0.959 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0044 | 1 | 1 |
Echinococcus multilocularis | cyclin dependent kinase | 0.0044 | 1 | 1 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0044 | 1 | 1 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0044 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.2735 | 0.2735 |
Plasmodium falciparum | protein kinase 5 | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0043 | 0.959 | 0.959 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0044 | 1 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0043 | 0.959 | 0.959 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0044 | 1 | 1 |
Echinococcus granulosus | cyclin dependent kinase | 0.0044 | 1 | 1 |
Plasmodium vivax | protein kinase Crk2 | 0.0044 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0044 | 1 | 1 |
Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.0044 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0044 | 1 | 1 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0043 | 0.959 | 0.959 |
Giardia lamblia | Kinase, CMGC CDK | 0.0044 | 1 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0044 | 1 | 1 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0043 | 0.959 | 0.959 |
Onchocerca volvulus | 0.0043 | 0.959 | 0.5 | |
Trichomonas vaginalis | cyclin B, putative | 0.0043 | 0.959 | 0.959 |
Echinococcus multilocularis | cyclin B | 0.0043 | 0.959 | 0.959 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.